BNP Screening for PAH in Scleroderma PDF Print E-mail
Tuesday, 24 July 2012 19:41
An elevated level of N-terminal pro-brain natriuretic peptide (NT-proBNP) has a high sensitivity and specificity for pulmonary arterial hypertension in patients with systemic sclerosis (SSc-PAH), Australian rheumatologists and cardiologists have suggested.

They investigated a total of 94 patients with systemic sclerosis in four groups: one with SSc-PAH confirmed by right heart catheterisation, another considered at high risk because of findings on trans-thoracic echocardiography, a group with interstitial lung disease, and a group with no cardiopulmonary complications.

“NT-proBNP was highest in the PAH group compared with the other groups, and higher in the risk group compared with controls,” they said.

The marker was positively correlated with systolic and mean pulmonary artery pressure, pulmonary vascular resistance and mean right atrial pressure.

Further analysis defined thresholds for NT-proBNP and/or results on carbon monoxide pulmonary diffusion tests that should prompt investigation for possible PAH, for example with echocardiography, high-resolution CT, 6-minute walk test, and definitive right heart catheterisation when indicated.

PAH accounted for about 30% of deaths related to systemic sclerosis, the researchers said. In its earliest stages, patients were often asymptomatic or minimally symptomatic but early detection and treatment could delay progression and improve survival.

Annual echocardiography was recommended to screen for early PAH, but this strategy had limitations including technical challenges, insufficient reliability in the presence of coexisting lung disease, poor acoustic windows in some patients, the need for expertise, and issues of cost and resource allocation.

NT-proBNP was released by cardiac myocytes in response to increased ventricular wall stress. The blood test was now widely available given its importance in the diagnosis, prognosis and risk stratification of congestive cardiac failure, they said.

Source: James, T. (2012), "BNP screening for pulmonary arterial hypertension in systemic sclerosis"; Rheumatology Update; original article can be viewed here.

 
More articles :

» New Target Indentified In The Battle Against Rheumatoid Arthritis Identified

Researchers have uncovered the mechanism by which a cell signalling pathway contributes to the development of rheumatoid arthritis (RA). The study led by researchers at Hospital for Special Surgery, also provides proof that drugs under development...

» New Site For Adult Stem Cell Resources Launched

A new website is detailing success stories in adult stem cell research. is part of a campaign to educate and spread awareness about the potentials and successes of adult stem cell therapies, and was created by the Family Research Council and...

» Researchers Revisit Pulmonary Arterial Hypertension (PAH) Survival

Setting out to determine the survival of patients with (PAH), researchers at the University of Chicago Medical Center and their colleagues also discovered that an equation used for more than 20 years to predict survival is outdated. Accordingly,...

» Biomarker Shows Promise In Scleroderma

A biomarker that can be used to screen patients for has shown promise in a proof of concept study. Researchers from St Vincent’s in Melbourne found (ADMA) levels had an acceptable high specificity and sensitivity for detecting the complication,...

» Methotrexate Effective In Juvenile Localized Scleroderma

is effective in when given with a short course of steroids, an Italian randomized study confirmed.Among children ages 6 to 17 receiving methotrexate, 67.4% completed the yearlong trial without flaring, compared with 29.2% of those given placebo...

» Multidisciplinary Therapy May Improve Systemic Sclerosis

For patients with (SSc), a multidisciplinary program offers better improvement of grip strength, maximal mouth opening (MMO), six-minute walk distance (6MWD), and SSc Health Assessment Questionnaire (HAQ) score than regular outpatient care,...